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Abstract
 
The ability of the immune system to focus T cell responses against a select number of potential
epitopes of a complex antigen is termed immunodominance. Epitopes that trigger potent T cell
activation, after in vivo priming, are classified as immunodominant. By contrast, determinants
that fail to elicit any response are called cryptic. DM, a major histocompatibility complex
(MHC) heterodimer, plays a pivotal role in the presentation of MHC class II–restricted
epitopes by catalyzing the exchange of class II–associated invariant chain peptide with the anti-
gen-derived peptides within the MHC class II binding groove. Using L cells transfected with
genes for MHC class II, invariant chain, and DM, we have studied the contribution of DM in
the presentation of two cryptic (peptide 11–25 and peptide 20–35) and one dominant (peptide
106–116) epitope of hen egg white lysozyme (HEL). Cells lacking DM heterodimers efficiently
display the determinants HEL 11–25 and HEL 20–35 to T cells. Strikingly, however, cells ex-
pressing DM are severely compromised in their ability to present the cryptic HEL 11–25/A
 
d
 
and 20–35/A
 
d
 
 epitopes. DM-mediated antagonism of HEL 11–25/A
 
d
 
 and 20–35/A
 
d
 
 presenta-
tion could thus be central to 11–25/A
 
d
 
 and 20–35/A
 
d
 
 being cryptic epitopes in the HEL sys-
tem. Interestingly, the display of the immunodominant epitope of HEL, 106–116/E
 
d
 
, and of a
dominant epitope of sperm whale myoglobin (SWM), 102–118/A
 
d
 
, is entirely dependent on
the expression of DM. Thus, cells lacking DM molecules are unable to efficiently express HEL
106–116/E
 
d
 
 and SWM 102–118/A
 
d
 
 determinants. We conclude that the DM heterodimers di-
rect the immunodominant and cryptic fate of antigenic epitopes in vivo.
Key words: antigen determinant • antigen processing • H-2M • immunodominance • major 
histocompatibility complex class II
 
Introduction
 
The T cell response in the H-2
 
d
 
 haplotype mice immu-
nized with hen egg white lysozyme (HEL)
 
1
 
 is almost exclu-
sively directed towards a single immunodominant epitope
of HEL, peptide 106–116, bound to E
 
d
 
 MHC molecules
(106–116/E
 
d
 
; references 1–4). Immunization with HEL
does not elicit T cells specific for HEL 11–25 or HEL 20–
35 bound to A
 
d
 
 MHC (2–4). However, HEL 11–25/A
 
d
 
–
and to some degree, HEL 20–35/A
 
d
 
–specific T cells, can
be activated by immunization with the peptides 11–25 and
20–35, respectively (2). Peptides 11–25 and 20–35, which
require no further processing in order to be efficiently pre-
sented in the groove of the A
 
d
 
 molecules, thus encode
cryptic determinants in the BALB/c (H-2
 
d
 
) mice. Immu-
nodominance is a distinctive and classic characteristic of
most T cell immune responses (1, 5, 6). Nevertheless, the
molecular mechanisms dictating the immunodominant and
cryptic fate of T cell epitopes remain unknown.
Processing and presentation of exogenous protein anti-
gens taken up via the endocytic pathway involve the traf-
ficking of MHC class II molecules from the constitutive
secretory pathway to the endocytic compartment (contain-
ing the antigen-derived peptides), en route to the cell sur-
face (7, 8). This task is accomplished by a glycoprotein
called invariant chain (Ii) that enhances the transport of
MHC class II chains to the endocytic compartment (7, 8).
In addition, a fragment of Ii, called class II–associated in-
variant chain peptide (CLIP), occupies the peptide-binding
groove of MHC class II molecules (9) until DM, a nonclas-
sical MHC class II heterodimer, induces its release and re-
placement with peptides derived from foreign or endoge-
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nous antigens (7, 10–12). Due to a lysosomal targeting
signal encoded within the 
 
b
 
 chain of DM heterodimers,
DM is localized to endocytic MHC class II compartments
(13) where it has been shown to transiently bind MHC
class II molecules (12, 13). DM, in addition to catalyzing
the release of CLIP, has been shown to influence the bind-
ing of several non-CLIP peptides to the MHC class II mol-
ecules (11, 12, 14–17). DM mutant mice and APC lines
have been used to show that DM is required for presenta-
tion of certain foreign antigens (12). We have shown previ-
ously that expression of DM can increase, diminish, or
have a neutral effect on the presentation of different intra-
cellular self proteins (14, 18, 19). But the biological conse-
quence of the DM-mediated modification of the repertoire
of peptides displayed by the MHC molecules on expression
of the epitope specificity of T cell immune responsiveness
to a foreign or self antigen remains unexplored. We present
evidence here that DM directs the cryptic and immu-
nodominant fate of antigen determinants.
 
Materials and Methods
 
APCs.
 
L cells were initially transfected with genes encoding
A
 
d
 
 alone, and a positive clone was isolated and then supertrans-
fected with genes encoding genomic Ii (Ii or gIi) or Ii and mu-
rine DM. Derivation and characterization of these cells have
been described previously (14, 18). A
 
d
 
-positive cells expressing
either no cofactor, Ii alone, or Ii and H-2M (or murine DM,
hereafter referred to as DM) were then additionally transfected
with genes encoding E
 
d
 
, and positive cells were obtained by pre-
parative sorting using the E
 
a
 
-specific Ab 14-4-4S and magnetic
beads. Sorted and other transfected cells were grown in selection
media with appropriate drugs: A
 
d 
 
and A
 
d
 
-Ii L cells were cultured
in the presence of G418 (200 
 
m
 
g/ml; GIBCO BRL), A
 
d
 
-
Ii
 
1
 
DM, in G418 and blasticidin (100 
 
m
 
g/ml; Invitrogen), A
 
d
 
E
 
d
 
and A
 
d
 
E
 
d
 
-Ii, in G418 and HAT (GIBCO BRL), and finally
A
 
d
 
E
 
d
 
-Ii
 
1
 
DM, in HAT, G418, and blasticidin. Cells were trans-
ferred into normal media (14) containing no drugs 24–48 h be-
fore their use in T cell assays.
 
Flow Cytometry.
 
mAbs reacting with A
 
d
 
 (MKD6) or E
 
d
 
 (14-
4-4S) were obtained from the American Type Culture Collec-
tion and used as culture supernatants. Cell surface expression of
MHC class II molecules was evaluated by flow cytometry as
described (19). In brief, cells were incubated successively with
mAbs, followed by secondary step FITC-conjugated goat anti–
mouse Igs (IgA, IgG, and IgM, and FITC-conjugated goat anti–
mouse; Sigma-Aldrich), and were then analyzed on a FACScan™
cytofluorimeter (Becton Dickinson). Background fluores-
cence  was determined by incubating cells with media alone or
an irrelevant mAb, and then with FITC-conjugated goat anti–
mouse.
 
Western Blots.
 
Cells were harvested from culture by mild
trypsin treatment, washed extensively, and then counted. 8 
 
3
 
10
 
6
 
 cells of each type (cells expressing A
 
d
 
E
 
d
 
 alone, A
 
d
 
E
 
d
 
 Ii, or
A
 
d
 
E
 
d
 
 Ii
 
1
 
DM) were solubilized in 1.0 ml 0.5% Triton X-100
(Sigma-Aldrich) with protease inhibitors for 45 min on ice as de-
scribed previously (19). Nuclei and other insoluble debris were
pelleted by centrifugation and the supernatant was transferred to
a fresh tube. An equivalent aliquot of each cell lysate, equal to
8 
 
3
 
 10
 
5
 
 cell equivalents, was then adjusted to 2.0% SDS, 62 mM
Tris, pH 6.8, and 10% glycerol, boiled for 3 min, and then frac-
 
tionated by SDS-10% PAGE. After electrophoresis, proteins
were transferred to nitrocellulose, then processed for Western
blotting as described previously (19). Blots were first probed and
developed using nonspecific rat mAb or normal rabbit serum
Abs, and then probed specifically for Ii and DM protein expres-
sion, as indicated in the legend to Fig. 1 b. Ii was detected by
probing with the rat mAb In-1 (20), and DM
 
b
 
 was detected by
probing with a rabbit antisera raised against a synthetic peptide
corresponding to the COOH-terminal tail of the mouse DM
 
b
 
chain, conjugated to KLH. Binding of primary Abs to the blot
was detected with horseradish peroxidase–coupled secondary
goat Abs specific for either rat Ig, purchased from KPL Laborato-
ries, or rabbit Ig, purchased from Life Technologies. Western
blots were processed for chemiluminescence and autoradiogra-
phy as described previously (18).
 
Metabolic Labeling, Immunoprecipitation, and SDS-Gel Analy-
ses.
 
For analysis of Ii, and DM expression within the APC, 0.5 
 
3
 
10
 
6
 
 cells were plated in two 100-mm tissue culture dishes for 24 h.
The adherent cells were then prelabeled for overnight incubation
in MEM deficient in leucine with added [
 
3
 
H]leucine obtained
from NEN Life Science Products at 25 
 
m
 
Ci/ml. Ii, DM, and
MHC class I molecules were isolated from 1% Triton detergent
lysates by immunoprecipitation with either rabbit antisera specific
for the cytosolic tail of DM
 
b
 
, the rat mAb In-1 (20) reactive with
the cytosolic tail of Ii, or the class I–specific mAb 16.1.11N (21).
Immunoprecipitated proteins were fractionated by SDS-10%
PAGE and gels were stained with Coomassie brilliant blue, then
destained with 30% methanol/10% acetic acid. Stained and
destained gels were then washed with water, treated with Flouro-
Hance (Research Products International), dried, and exposed to
film at 
 
2
 
80
 
8
 
C.
 
Antigens and Peptides.
 
HEL was either purified as described
previously (22) or was obtained from Sigma-Aldrich as a purified
preparation. Both preparations of HEL gave analogous results.
Sperm whale myoglobin (SWM) was obtained form Accurate
Chemicals and Scientific Corp. Peptides HEL 11–25, HEL 20–
35, HEL 106–116, and SWM 102–118 were synthesized and pu-
rified by Macromolecular Resources.
 
T Cell Hybrids.
 
The cloned T cell hybridomas ISG-9-49,
ISG-9-69, and 17.B.8.1 were obtained from continuously grow-
ing HEL-specific T cell lines derived from LN cells of HEL-
primed B10.GD mice as described previously (22, 23). The
cloned T hybrids D2-4-18 and D2-4-8 were obtained from
HEL-specific T cell lines derived from LN cells of B10.D2 mice
immunized with HEL (22, 23). In brief, T cell blasts from T cell
lines were fused with the TCR
 
a
 
2
 
b
 
2
 
 variant of BW5147 as a fu-
sion partner and cloned by limiting dilution in the presence of
HEL. HEL-reactive hybrids were further analyzed for recogni-
tion of peptides. The hybrid C7-R14, specific for SWM 102–118
(24, 25), was a gift from Dr. Jay Berzofsky (National Institutes of
Health, Bethesda, MD).
 
Assay of T Cell Responses.
 
T hybridoma cells (10
 
5
 
) were cul-
tured with 1–5 
 
3
 
 10
 
4
 
 of either A
 
d
 
 or A
 
d
 
E
 
d
 
 APCs, A
 
d
 
-Ii or
A
 
d
 
E
 
d
 
-Ii APCs, or A
 
d
 
-Ii
 
1
 
DM or A
 
d
 
E
 
d
 
-Ii
 
1
 
DM APCs with differ-
ent concentrations of HEL, SWM, or peptide (22, 23), as indi-
cated in the figure legends (Figs. 2–5). Fixed APCs, where indi-
cated, were treated with 1% formaldehyde in PBS for 12 min,
then washed extensively before use. All cultures were done in
triplicate. The culture supernatants collected 24 h later were as-
sayed for IL-2 by ELISA as described previously (26). The sub-
strate used was 
 
O
 
-phelylenediamine dihydrochloride (Sigma-
Aldrich). Absorption at 490 nm was measured using a microplate
reader (Molecular Devices). 
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Results
 
Cloned populations of L cells deficient in MHC class II,
Ii, and DM heterodimers (DM) were transfected with
genes encoding A
 
d
 
 MHC molecules followed by either Ii
or Ii and DM (Ii
 
1
 
DM), as described previously (14, 19).
The A
 
d
 
, A
 
d
 
-Ii, and A
 
d
 
-Ii
 
1
 
DM L cell lines were further
transfected with genes for E
 
d
 
 MHC molecules. Fig. 1
shows the characterization of L cells transfected with A
 
d
 
and/or A
 
d
 
E
 
d
 
 MHC molecules, together with genes for ei-
ther Ii only or with Ii and the DM heterodimers (Ii
 
1
 
DM).
It is clear that the expression of MHC class II is optimal in
cells expressing both the Ii and DM (Fig. 1 a), as has been
observed previously (14, 27). Protein expression of Ii and
DM are shown in Fig. 1, b and c, confirming that the orig-
inal cell lines used for transfection lack the constitutive ex-
pression of Ii and DM glycoproteins, and that protein ex-
pression of Ii and DM was readily detected in the
appropriate cells.
 
DM Extinguishes Presentation of the Cryptic Epitopes of HEL
Presentation of Cryptic Epitope HEL 11–25.
 
Fig. 2 shows
the display of the cryptic HEL determinant 11–25 by A
 
d
 
E
 
d
 
L cells used as APCs at different concentrations of HEL.
The determinant display was examined by analyzing activa-
tion of two different cloned T cell hybridomas, ISG9-49
and ISG-9-69, that recognize HEL 11–25/A
 
d
 
 and were de-
rived as described previously (22; see Materials and Meth-
ods). It is clear that the A
 
d
 
E
 
d
 
-Ii APCs, lacking expression of
DM heterodimers, can efficiently process HEL and present
the cryptic epitope 11–25. The display of 11–25 epitope by
the A
 
d
 
E
 
d
 
-Ii APCs can be observed at even low (0.2–2 
 
m
 
M)
concentrations of HEL. Most strikingly, the presentation of
11–25 was nearly extinguished, even at 
 
.
 
30-
 
m
 
M concen-
trations of HEL, when presented by APCs that express DM
in addition to Ii (Fig. 2). The peptide 11–25, which re-
quires no further processing, is equivalently presented by
APCs with Ii alone and with Ii
 
1
 
DM (insets, Fig. 2, a and
b), despite the fact that APCs that express Ii alone display
lower levels of MHC class II molecules than Ii
 
1
 
DM APCs
(Fig. 1 a). To further confirm DM-mediated antagonism of
presentation of the epitope 11–25, we used an additional
set of APCs, the A
 
d
 
 APCs, expressing either Ii alone or
Ii
 
1
 
DM. Once again, the presentation of the cryptic
Figure 1. Flow cytometry and biochemical analyses of L cells express-
ing class II molecules with or without Ii and DM. (a) Cells expressing the
indicated class II gene (either Ad alone or Ad and Ed) with or without the
additional expression of Ii or Ii and DM (Ii1DM) were analyzed for sur-
face expression of class II by flow cytometry using the Ad- specific mAb
MKD6 (I-Ad, dotted lines) or the I-E–specific Ab 14.4-4S (I-Ed, thick
lines), and a second step FITC-labeled Ig, as described in Materials and
Methods. Background fluorescence is represented with thin lines. Flow
cytometry profiles are derived by analyses of the stained cells on a FAC-
Scan™ flow cytometer. (b) Western blot analysis. Cells expressing class II
(AdEd) alone (exv), class II1Ii (Ii), or class II1Ii1DM (DMI) were har-
vested from culture and lysed in detergent. An equal aliquot of the pro-
teins from each detergent lysate was fractionated by SDS-10% PAGE and
transferred to nitrocellulose. Blots were probed with either nonspecific
Abs (a control rat mAb or normal rabbit serum [NRS]), then processed
for chemiluminescent detection with horseradish peroxidase–coupled
secondary Abs. After autoradiography the same blots were then probed
with the rat anti-Ii mAb In-1 (reference 20), or a rabbit antisera specific
for the cytosolic tail of murine DMb, as indicated in the figure. Shown
on the right of the figure are the positions of Ii p31 and DMb. (c) Long-term radiolabeling and immunoprecipitation. Cells expressing class II alone
(AdEd-exv), class II1Ii (AdEd1Ii) or class II1Ii1DM (AdEd1Ii1DM) were radiolabeled overnight with [3H]leucine as described in Materials and Meth-
ods. Postnuclear supernatants of detergent lysates were incubated with either control Abs (NRS), the class I Kk–specific Ab 16.1.11N (reference 21), the
anti-DM antisera, or the Ii-specific mAb In-1. Antigen–Ab complexes were isolated with protein A–Sepharose. Immunoprecipitated proteins were
eluted in 2% SDS and then fractionated by SDS-PAGE under reducing conditions. After electrophoresis, the gel was processed for autoradiography and
then exposed to film. Shown to the left of the figure are the positions of molecular weight markers run in parallel. On the right of the figure are the po-
sitions of class I Kk, Ii, DMa, and DMb chains. Specific bands for DMa and DMb (positions indicated on the right side of c) are seen only in the APC
line transfected with DM. However, a nonspecific band, isolated with the rabbit antisera (normal rabbit serum and anti-DM Ab), detectable just below
the class I heavy chain, can be seen in all of the three APC lines. Ii expressed in these cells displays primarily the p31 form of Ii, marked on the gel, with
minor amounts of the p41 form of Ii, detected upon long exposures of the gel to film (not shown).784 DM Determines the Cryptic and Immunodominant Fate of Antigenic Epitopes
epitope 11–25 was dramatically diminished when DM
molecules were expressed by the APCs. Ad-Ii and AdEd-Ii
APCs lacking DM molecules were clearly very active at
presenting this cryptic epitope in the absence of DM (Figs.
2 and 3). In addition, we used fixed APCs for presentation
of the cryptic epitope 11–25 to address the question
whether the Ad-Ii APCs were able to effectively present
the cryptic HEL 11–25 simply by virtue of being more effi-
cient in taking up either denatured HEL or any other con-
taminants of HEL. As is evident in Fig. 3, b and d, the fixed
Ad-Ii or Ad-Ii1DM APCs are unable to present HEL even
at the highest concentration, 100 mM, of HEL. The com-
petence of the Ad-Ii APCs to present the cryptic epitope is
thus solely due to proficient intracellular processing of
HEL. Results obtained using a third 11–25/Ad–specific
cloned T hybrid, GD-5-42, additionally validated the DM-
mediated antagonism of presentation of 11–25/Ad, even
at high concentrations (25–100 mM) of HEL (data not
shown).
Presentation of Cryptic Epitope HEL 20–35. Fig. 4 shows
the display of an additional cryptic epitope of HEL, 20–35/
Ad, by Ad APCs. Interestingly, presentation of this second
cryptic epitope of HEL was also antagonized by the expres-
sion of DM within APCs. Once again, Ad-Ii APCs were
able to present this epitope very efficiently to 20–35–spe-
cific T cells, 17B.8.1. However, Ad-Ii1DM APCs were
severely compromised in their ability to display this
epitope. The fixed Ad-Ii or Ad-Ii1DM APCs, as shown for
the 11–25/Ad cryptic epitope, were unable to present this
epitope from HEL at even the highest concentration of
HEL tested (Fig. 4 b), thus ruling out the possibility that
the expression of the epitope 20–35/Ad was a result of effi-
cient uptake of denatured HEL.
DM Stimulates Presentation of the Immunodominant Determi-
nants of HEL and SWM. We then examined the display
of the immunodominant determinant of HEL, 106–116/
Figure 2. DM extinguishes the display of the cryptic 11–25/Ad epitope
of HEL using AdEd APCs. Responses of T hybrids (a) ISG-9-49 and (b)
ISG-9-69, specific for HEL 11–25, are shown at different concentrations
of HEL using L cells expressing Ad, Ed, and Ii (AdEd-Ii APC) (d), and L
cells expressing Ad, Ed, Ii, and DM (AdEd-Ii1DM APC) (j). The activa-
tion of these T hybrids is measured by release of IL-2, depicted as ng/ml.
IL-2 was analyzed by ELISA as described previously (reference 26; see
Materials and Methods). The insets show stimulation of respective T hy-
brids using AdEd-Ii APCs (s), or AdEd-Ii1DM APCs (h) at different
concentrations of peptide (p) HEL 11–25. The data are shown as mean 6
SE of triplicate cultures. Responses of T hybrids using AdEd APCs (lack-
ing Ii and DM) to different doses of HEL were lower than those using the
AdEd-Ii APCs, but higher than those obtained using AdEd-Ii 1DM APCs
(data not shown).
Figure 3. DM extinguishes the display of the cryptic 11–25/Ad epitope
of HEL using Ad APCs. Responses of T hybrids (a and b) ISG-9-49 and
(c and d) ISG-9-69 are shown at different concentrations of HEL using L
cells expressing Ad and Ii (Ad-Ii APC) (d), and L cells expressing Ad, Ii,
and DM (Ad-Ii1DM APC) (j). The results are expressed as described in
the legend to Fig. 2. The insets show stimulation of respective T hybrids
using Ad-Ii APCs (s) or Ad-Ii1DM APCs (h) at different concentrations
of peptide (p) HEL I1–25. Normal, unfixed APCs were used in a and c,
and fixed APCs (see Materials and Methods) were used in b and d.785 Nanda and Sant
Ed, by AdEd APCs using the cloned T cell hybrids D2-4-18
and D2-4-8. Fig. 5 shows that in sharp contrast to our ob-
servations for the HEL 11–25 and 20–35 determinants (Fig.
2), AdEd-Ii APCs, lacking DM molecules, were very poor at
displaying this immunodominant epitope (Fig. 5), whereas
cells additionally expressing DM showed efficient presenta-
tion. The half-maximal response of the T cell hybrid D2-4-
18 was obtained at 2 mM HEL using AdEd-Ii1DM APCs.
However, the activation of this T hybrid essentially re-
mained at the baseline levels at concentrations of up to 33.3
mM HEL, using AdEd-Ii APCs lacking DM. Optimal pro-
cessing and display of this immunodominant determinant is
thus dependent on the expression of DM molecules. Fur-
thermore, these results attest that the AdEd-Ii1DM APCs are
functionally competent and the abrogation of presentation of
the cryptic 11–25 determinant in the presence of DM was
not due to some non-DM–related factor expressed by the
Ii1DM APCs. The data presented in the insets (Fig. 5, a and
b) show that the AdEd-Ii and AdEd-Ii1DM APCs were able
to stimulate the 106–116/Ed T cells equivalently when the
peptide HEL 106–116, which requires no further processing
(data not shown), was used. These results indicate the lack of
any intrinsic deficiency in AdEd-Ii APCs to interact with
106–116/Ed–specific T cells.
To pursue the argument that one function of the DM
molecules is to play a role in the manifestation of immune
dominance upon immunization with protein antigens, we
examined the effect of DM on the presentation of a domi-
nant determinant of SWM (23). Fig. 6 shows that just like
the immunodominant epitope 106–116/Ed of HEL, the op-
timal display of the immunodominant 102–118/Ad determi-
nant of SWM (23, 24) by Ad APCs was dependent on ex-
pression of DM in these APCs. The half-maximal response
of SWM 102–118–specific C7-R14 T cell hybrids stimu-
lated by the Ad-Ii1DM APCs was induced at only z1 mM
SWM, while a similar response by the Ad-Ii APCs was in-
duced at 60 mM SWM. Again, the results in Fig. 6 not only
support the conclusion that the immunodominant fate of T
cell determinants is dependent on the expression of DM, but
they also affirm that the failure of our set of Ad-Ii1DM
APCs (Figs. 3 and 4) to present the cryptic epitope 11–25 is
unrelated to any non-DM–related attribute of these cells.
Discussion
The focusing of T cell responses directed to protein anti-
gens to only a limited number of potential T cell epitopes is
Figure 4. DM extinguishes the display of the cryptic 20–35/Ad epitope
of HEL using Ad APCs. Response of T hybrid (a and b) 17B.8.1 is shown
at different concentrations of HEL using Ad-Ii APCs (d) and Ad-Ii1DM
APCs (j). The results are expressed as described in the legend to Fig. 1.
The insets show the stimulation of the T hybrid using Ad-Ii APCs (s) or
Ad-Ii1DM APCs (h) at different concentrations of peptide (p) HEL 20–
35. Normal, unfixed APCs were used in a, and fixed APCs (as described
in Materials and Methods) were used in b.
Figure 5. DM stimulates the presentation of the immunodominant
106–116/Ed epitope of HEL. Responses of T hybrids (a) D2-4-18 and (b)
D2-4-8, specific for HEL 106–116, are shown at different concentrations
of HEL using AdEd-Ii APCs (d) and AdEd-Ii1DM APC APCs (j). The
insets show the stimulation of respective T hybrids using different con-
centrations of peptide (p) HEL 106–116. The results are expressed as de-
scribed in the legend to Fig. 2.786 DM Determines the Cryptic and Immunodominant Fate of Antigenic Epitopes
a classical feature of antigen-specific immune responses (1,
5, 6). The evolutionary development of this basic principle
appears to be to accomplish (a) avoidance of activation of
an army of T cells unnecessary for a successful attack on a
pathogen; and (b) construction of an effective regulatory T
cell system directed towards a small subset of T cells (28)
specific for the immunodominant epitopes. T cell responses
directed towards complex pathogens such as Leishmania
have been shown to be, astonishingly, focused on a single
immunodominant epitope (29, 30). A variety of concepts
including determinant capture, nature of APCs, proteolytic
enzymes in distinct intracellular microenvironments, lym-
phokines, and general antigen processing have been pro-
posed to explain this classic feature of the immune system
(1, 3, 31–33). The molecular mechanisms to explain these
hypotheses still remain undetermined. We now show that
DM, an MHC-encoded heterodimer, previously shown by
us and others (14, 16, 17) to influence the repertoire of
self-peptides loaded onto MHC class II molecules, may
well be the guide that directs the antigen-derived peptides
to have either an immunodominant fate or a cryptic fate.
The two immunodominant determinants (HEL 106–116/Ed
and SWM 102–118/Ad) examined by us are dependent
on DM for presentation (Figs. 5 and 6). A third, the Leish-
mania-derived, immunodominant determinant Leishmania
homologue of receptors for activated C-kinase (LACK [29,
30]) 161–173/Ad, also requires the expression of DM mol-
ecules in order to be displayed on the surface of APCs (data
not shown). In the case of HEL (and perhaps also of other
protein antigens), DM determines the immunodominant
fate of epitopes by strongly augmenting the presentation of
the dominant determinant, 106–116/Ed, on APCs, while
simultaneously extinguishing the expression of the two
cryptic epitopes studied in this report, 11–25/Ad and 20–
35/Ad. DM-mediated antagonism was also observed for the
display of 74–96, a minor cryptic epitope (4, 23) of HEL
(our preliminary observations, not shown). The results re-
ported here also indicate that the cryptic fate of the 11–25/
Ad epitope is clearly not due to “determinant capture” (1).
The concept of determinant capture predicts that during
the creation of the dominant 106–116/Ed determinant (1),
the denatured HEL molecule would bind to Ed MHC,
and the portion of HEL outside the binding groove (includ-
ing the 11–25 region) would get digested by proteolytic
enzymes (1, 31). This outcome of the determinant capture
is expected to be independent of expression of Ii and DM
within APCs. Since the AdEd-Ii APCs are able to process
and present this epitope remarkably efficiently (Fig. 2), it is
clear that the Ed MHC molecules, while “capturing” the
dominant epitope HEL 106–116/Ed, are not responsible
for destroying the 11–25 epitope. Instead, it is the expres-
sion, or lack of DM molecules in APCs, that determines
the presentation of the cryptic epitope.
Our results are intriguing to consider in light of an earlier
report that the dendritic cells, but not B cells, focus T cell
responses against the immunodominant peptide of HEL
and are unable to present the peptide HEL 7–31 (34). One
possible explanation for this differential determinant display
could be the cell type–specific expression within B cells,
but not dendritic cells, of DO (35), an additional MHC
class II heterodimer that has been shown to inhibit the
function of DM molecules (35, 36). It has been shown that
DM specifically induces the release of the MHC-bound
peptides that display a lower binding stability, while favor-
ing the binding of peptides that show a higher stability of
binding MHC class II molecules (17). In view of the opti-
mal DM function and expression in the acidic endosomal
or lysosomal compartments (11, 16, 17), we examined
MHC binding and display of these peptides using fixed
APCs (37) at a variety of pH. We found that at a pH be-
tween 4 and 5, a 10-fold lower concentration of the immu-
nodominant peptide (106–116/Ed) was able to result in
half-maximal stimulation compared with the stimulatory
requirements for the cryptic peptide (11–25/Ad). However,
at pH 7.0, equivalent concentrations of both peptides were
needed for half maximal stimulation (data not shown).
These observations could be the result of distinct pH op-
tima of peptide binding to Ed (zpH 4.5) and Ad molecules
(zpH 5.5), differential off-rates for the two peptides at the
lower pH (38), or effects of DM expressed on the surface of
cells, as has been shown in a recent report (39).
It has been proposed that the DM-induced editing of the
repertoire of MHC class II–bound peptides could be a
function of differential off-rates of the peptide–MHC bind-
ing, leading to differences in the stability of the peptide–
MHC complexes (17, 40). In addition, it can be envisaged
that DM would selectively enhance the peptide binding
within the MHC–peptide complexes that show optimal
binding at lower pH, leading to the immunodominance of
such epitopes. In this context, it is interesting that the only
immunodominant epitope in both the HEL/H-2d and cy-
tochrome c/H-2k systems (41), and one of two dominant
epitopes in the SWM/H-2d system (24), are restricted by
I-E molecules (the latter with lower pH optima than the I-A
Figure 6. DM stimulates the presentation of the immunodominant
102–118/Ad epitope of SWM. Responses of SWM 102–118–specific T
hybrid C7-R14 are shown at different concentrations of SWM using
Ad-Ii APCs (d) and Ad-Ii1DM APCs (j). The results are expressed as
described in the legend to Fig. 2. The peptide (p) shown in the inset is
SWM 102–118.787 Nanda and Sant
molecules). The precise features that contribute to the
DM-mediated effects on the differential display of peptides
as seen in the current report, including the relative stability
of the 11–25/Ad and 106–116/Ed complexes using purified
MHC molecules, which is yet undetermined, are avenues
of future investigations.
In summary, we propose that the cryptic and immu-
nodominant fate of antigenic epitopes is a consequence of
the ability of DM to skew the repertoire of peptides dis-
played by the MHC class II molecules. Our results that ex-
pression of DM within APCs is able to dictate the fate of
two cryptic and three dominant epitopes testify that the
DM-mediated decree of the nature of an antigenic epitope
could be a general phenomenon. This function of DM may
have evolved in parallel with the “immunodominance” at-
tribute of the immune system as a mechanism to trigger
only selective T cell responses essential to fight a pathogen.
It is now becoming clear that one is tolerant to only the
dominant determinants of self-proteins and that the T cell
repertoire to the cryptic determinants remains intact in the
host (5, 42, 43). It is the T cell repertoire to the cryptic
self-epitopes that becomes activated in autoimmune disease
(5, 42, 43). Any variation in the levels or activity of DM
heterodimers thus may have consequences for autoimmu-
nity as well as response to pathogens.
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